High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk

BBA Clinical

Volumn 3, Issue , 2015, Pages 175-188

  Hafiane, Anouar ^a   Genest, Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Apolipoprotein A I; Atherosclerosis; Biomarkers of cardiovascular risk; Cellular cholesterol efflux; Coronary artery disease; High density lipoproteins; Vascular endothelial function

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIPIDOME; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; VASCULAR CELL ADHESION MOLECULE 1;

ANION EXCHANGE; ANTI INFLAMMATORY ASSAY; ANTIOXIDANT ASSAY; CARDIOVASCULAR RISK; CHOLESTEROL EFFLUX ASSAY; ENZYMATIC ASSAY; ENZYME ACTIVITY; GEL FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTACHOPHORESIS; LIPID ANALYSIS; LIPID OXIDATION; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NUCLEAR MAGNETIC RESONANCE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SHEAR STRESS; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULTRACENTRIFUGATION; VERTICAL AUTO PROFILING;

EID: 84924116950     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.01.005     Document Type: Review

References (202)

1. Boekholdt S.M., Arsenault B.J., Hovingh G.K., Mora S., Pedersen T.R., Larosa J.C., Welch K.M., Amarenco P., Demicco D.A., Tonkin A.M., et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 2013, 128:1504-1512.
2. Toth P.P., Barter P.J., Rosenson R.S., Boden W.E., Chapman M.J., Cuchel M., D'Agostino R.B., Davidson M.H., Davidson W.S., Heinecke J.W., et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J. Clin. Lipidol. 2013, 7:484-525.
3. Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., Hindy G., Holm H., Ding E.L., Johnson T., et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012, 380:572-580.
4. Rader D.J. Spotlight on HDL biology: new insights in metabolism, function, and translation. Cardiovasc. Res. 2014, 103:337-340.
5. Hafiane A., Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol 2013, 2013:891403.
6. Freeman L.A. Native-native 2D gel electrophoresis for HDL subpopulation analysis. Methods Mol. Biol. 2013, 1027:353-367.
7. Sorci-Thomas M.G., Owen J.S., Fulp B., Bhat S., Zhu X., Parks J.S., Shah D., Jerome W.G., Gerelus M., Zabalawi M., et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J. Lipid Res. 2012, 53:1890-1909.
8. Yassine H., Borges C.R., Schaab M.R., Billheimer D., Stump C., Reaven P., Lau S.S., Nelson R. Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin. Appl. 2013, 7:528-540.
9. Kontush A., Lhomme M., Chapman M.J. Unraveling the complexities of the HDL lipidome. J. Lipid Res. 2013, 54:2950-2963.
10. Besler C., Luscher T.F., Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol. Med. 2012, 4:251-268.
11. Riwanto M., Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid Res. 2013, 54:3227-3243.
12. Huang Y., Wu Z., Riwanto M., Gao S., Levison B.S., Gu X., Fu X., Wagner M.A., Besler C., Gerstenecker G., et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest. 2013, 123:3815-3828.
13. Sorrentino S.A., Besler C., Rohrer L., Meyer M., Heinrich K., Bahlmann F.H., Mueller M., Horvath T., Doerries C., Heinemann M., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121:110-122.
14. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am. J. Cardiol. 2009, 104:10E-15E.
15. van der Steeg W.A., Holme I., Boekholdt S.M., Larsen M.L., Lindahl C., Stroes E.S., Tikkanen M.J., Wareham N.J., Faergeman O., Olsson A.G., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 2008, 51:634-642.
16. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291.
17. Schaefer E.J. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?. Curr. Opin. Lipidol. 2013, 24:259-264.
18. Rohatgi A., Khera A., Berry J.D., Givens E.G., Ayers C.R., Wedin K.E., Neeland I.J., Yuhanna I.S., Rader D.R., de Lemos J.A., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 2014, 371:2383-2393.
19. Rosenson R.S. Functional assessment of HDL: moving beyond static measures for risk assessment. Cardiovasc. Drugs Ther. 2010, 24:71-75.
20. Rosenson R.S., Brewer H.B., Chapman M.J., Fazio S., Hussain M.M., Kontush A., Krauss R.M., Otvos J.D., Remaley A.T., Schaefer E.J. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57:392-410.
21. Degoma E.M., Rader D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 2011, 8:266-277.
22. Rosenson R.S., Brewer H.B., Ansell B., Barter P., Chapman M.J., Heinecke J.W., Kontush A., Tall A.R., Webb N.R. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013, 128:1256-1267.
23. Chapman M.J., Goldstein S., Lagrange D., Laplaud P.M. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 1981, 22:339-358.
24. Johansson J., Carlson L.A., Landou C., Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler. Thromb. 1991, 11:174-182.
25. Asztalos B.F., Collins D., Horvath K.V., Bloomfield H.E., Robins S.J., Schaefer E.J. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 2008, 57:77-83.
26. Collins L.A., Mirza S.P., Kissebah A.H., Olivier M. Integrated approach for the comprehensive characterization of lipoproteins from human plasma using FPLC and nano-HPLC-tandem mass spectrometry. Physiol. Genomics 2010, 40:208-215.
27. Marz W., Siekmeier R., Scharnagl H., Seiffert U.B., Gross W. Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins. Clin. Chem. 1993, 39:2276-2281.
28. Warnick G.R., Albers J.J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J. Lipid Res. 1978, 19:65-76.
29. Warnick G.R., Nauck M., Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin. Chem. 2001, 47:1579-1596.
30. Miida T., Nishimura K., Okamura T., Hirayama S., Ohmura H., Yoshida H., Miyashita Y., Ai M., Tanaka A., Sumino H., et al. Validation of homogeneous assays for HDL-cholesterol using fresh samples from healthy and diseased subjects. Atherosclerosis 2014, 233:253-259.
31. Cole T.G., Contois J.H., Csako G., McConnell J.P., Remaley A.T., Devaraj S., Hoefner D.M., Mallory T., Sethi A.A., Warnick G.R. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 2013, 59:752-770.
32. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 1982, 28:1379-1388.
33. Contois J.H., Albert A.L., Nguyen R.A. Immunoprecipitation of apolipoprotein B-containing lipoproteins for isolation of HDL particles. Clin. Chim. Acta 2014, 436C:348-350.
34. Kimberly M.M., Leary E.T., Cole T.G., Waymack P.P. Selection, validation, standardization, and performance of a designated comparison method for HDL-cholesterol for use in the cholesterol reference method laboratory network. Clin. Chem. 1999, 45:1803-1812.
35. Bachorik P.S., Albers J.J. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 1986, 129:78-100.
36. Jahani M., Huttash R.G., Lacko A.G. A novel chromatographic method for the preparation of high density lipoproteins. Prep. Biochem. 1980, 10:431-444.
37. de la Llera-Moya M., Drazul-Schrader D., Asztalos B.F., Cuchel M., Rader D.J., Rothblat G.H. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 2010, 30:796-801.
38. Patel P.J., Khera A.V., Jafri K., Wilensky R.L., Rader D.J. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J. Am. Coll. Cardiol. 2011, 58:2068-2075.
39. Warnick G.R., Nguyen T., Albers A.A. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin. Chem. 1985, 31:217-222.
40. Nauck M., Warnick G.R., Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin. Chem. 2002, 48:236-254.
41. Watanabe J., Grijalva V., Hama S., Barbour K., Berger F.G., Navab M., Fogelman A.M., Reddy S.T. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J. Biol. Chem. 2009, 284:18292-18301.
42. Langlois M.R., Delanghe J.R., De Buyzere M., Rietzschel E., De Bacquer D. Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side?. Atherosclerosis 2013, 226:296-298.
43. Contois J.H. A Critical Review of LDL Cholesterol and HDL Cholesterol Measurement. Sun Diagnostics, LLC http://www.sundiagnostics.us/wp-content/uploads/2012/09/white-paper-a-critical-review-of-hdl-and-ldl-measurement.pdf.
44. Alwaili K., Bailey D., Awan Z., Bailey S.D., Ruel I., Hafiane A., Krimbou L., Laboissiere S., Genest J. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim. Biophys. Acta 2012, 1821:405-415.
45. Miller W.G., Myers G.L., Sakurabayashi I., Bachmann L.M., Caudill S.P., Dziekonski A., Edwards S., Kimberly M.M., Korzun W.J., Leary E.T., et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin. Chem. 2010, 56:977-986.
46. Schaefer E.J., Otokozawa S., Ai M. Limitations of direct methods and the reference method for measuring HDL and LDL cholesterol. Clin. Chem. 2011, 57:1081-1083. (author reply 1083).
47. De Lalla O.F., Gofman J.W. Ultracentrifugal analysis of serum lipoproteins. Methods Biochem. Anal. 1954, 1:459-478.
48. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 2008, 54:788-800.
49. Kontush A., Chantepie S., Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1881-1888.
50. Guerin M., Lassel T.S., Le Goff W., Farnier M., Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 2000, 20:189-197.
51. Chung B.H., Wilkinson T., Geer J.C., Segrest J.P. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J. Lipid Res. 1980, 21:284-291.
52. Kulkarni K.R. Cholesterol profile measurement by vertical auto profile method. Clin. Lab. Med. 2006, 26:787-802.
53. May H.T., Nelson J.R., Kulkarni K.R., Anderson J.L., Horne B.D., Bair T.L., Muhlestein J.B. A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/[VLDL(3)+IDL]). Lipids Health Dis. 2013, 12:55.
54. Chung B.H., Segrest J.P., Ray M.J., Brunzell J.D., Hokanson J.E., Krauss R.M., Beaudrie K., Cone J.T. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1986, 128:181-209.
55. Kulkarni K.R., Marcovina S.M., Krauss R.M., Garber D.W., Glasscock A.M., Segrest J.P. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J. Lipid Res. 1997, 38:2353-2364.
56. Segrest J.P., Cheung M.C., Jones M.K. Volumetric determination of apolipoprotein stoichiometry of circulating HDL subspecies. J. Lipid Res. 2013, 54:2733-2744.
57. Kunitake S.T., Kane J.P. Factors affecting the integrity of high density lipoproteins in the ultracentrifuge. J. Lipid Res. 1982, 23:936-940.
58. Davidsson P., Hulthe J., Fagerberg B., Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2010, 30:156-163.
59. 2O/sucrose or in KBr. J. Lipid Res. 2008, 49:481-490.
60. Rooke J.A., Skinner E.R. The dissociation of apolipoproteins from rat plasma lipoproteins during isolation by precipitation with polyanions. Int. J. Biochem. 1979, 10:329-335.
61. Fainaru M., Glangeaud M.C., Eisenberg S. Radioimmunoassay of human high density lipoprotein apo-protein A-1. Biochim. Biophys. Acta 1975, 386:432-443.
62. Hara I., Okazaki M. High-performance liquid chromatography of serum lipoproteins. Methods Enzymol. 1986, 129:57-78.
63. Hirowatari Y., Yoshida H., Kurosawa H., Doumitu K.I., Tada N. Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. J. Lipid Res. 2003, 44:1404-1412.
64. Anantharamaiah G.M., Jones J.L., Brouillette C.G., Schmidt C.F., Chung B.H., Hughes T.A., Bhown A.S., Segrest J.P. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 1985, 260:10248-10255.
65. Awan Z., Bailey D., Hafiane A., Genest J. Acquired severe hypercholesterolemia and hypoalphalipoproteinemia. J. Clin. Lipidol. 2009, 3:393-397.
66. Diditchenko S., Gille A., Pragst I., Stadler D., Waelchli M., Hamilton R., Leis A., Wright S.D. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2202-2211.
67. Yoshida H. Clinical significance of lipoprotein analysis method by HPLC. Rinsho Byori 2010, 58:1093-1098.
68. Wiesner P., Leidl K., Boettcher A., Schmitz G., Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 2009, 50:574-585.
69. Usui S., Nakamura M., Jitsukata K., Nara M., Hosaki S., Okazaki M. Assessment of between-instrument variations in a HPLC method for serum lipoproteins and its traceability to reference methods for total cholesterol and HDL-cholesterol. Clin. Chem. 2000, 46:63-72.
70. Innis-Whitehouse W., Li X., Brown W.V., Le N.A. An efficient chromatographic system for lipoprotein fractionation using whole plasma. J. Lipid Res. 1998, 39:679-690.
71. Dong J., Guo H., Yang R., Li H., Wang S., Zhang J., Zhou W., Chen W. A novel and precise method for simultaneous measurement of serum HDL and LDL subfractions and lipoprotein (a) cholesterol by ultracentrifugation and high-performance liquid chromatography. Clin. Chim. Acta 2012, 413:1071-1076.
72. Nichols A.V., Krauss R.M., Musliner T.A. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 1986, 128:417-431.
73. Tian L., Long S., Li C., Liu Y., Chen Y., Zeng Z., Fu M. High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes. Lipids Health Dis. 2012, 11:54.
74. Asztalos B.F., Tani M., Schaefer E.J. Metabolic and functional relevance of HDL subspecies. Curr. Opin. Lipidol. 2011, 22:176-185.
75. Bailey D., Jahagirdar R., Gordon A., Hafiane A., Campbell S., Chatur S., Wagner G.S., Hansen H.C., Chiacchia F.S., Johansson J., et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 2010, 55:2580-2589.
76. Rainwater D.L., Andres D.W., Ford A.L., Lowe F., Blanche P.J., Krauss R.M. Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. J. Lipid Res. 1992, 33:1876-1881.
77. Kunitake S.T., La Sala K.J., Kane J.P. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J. Lipid Res. 1985, 26:549-555.
78. Asztalos B.F., Schaefer E.J. High-density lipoprotein subpopulations in pathologic conditions. Am. J. Cardiol. 2003, 91:12E-17E.
79. Miyazaki O., Ogihara J., Fukamachi I., Kasumi T. Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in plasma. J. Lipid Res. 2014, 55:214-225.
80. Asztalos B.F., Roheim P.S. Presence and formation of 'free apolipoprotein A-I-like' particles in human plasma. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1419-1423.
81. Miida T., Miyazaki O., Nakamura Y., Hirayama S., Hanyu O., Fukamachi I., Okada M. Analytical performance of a sandwich enzyme immunoassay for pre beta 1-HDL in stabilized plasma. J. Lipid Res. 2003, 44:645-650.
82. Bottcher A., Schlosser J., Kronenberg F., Dieplinger H., Knipping G., Lackner K.J., Schmitz G. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions. J. Lipid Res. 2000, 41:905-915.
83. Schmitz G., Mollers C., Richter V. Analytical capillary isotachophoresis of human serum lipoproteins. Electrophoresis 1997, 18:1807-1813.
84. Zhang B., Maeda N., Okada K., Tatsukawa M., Sawayama Y., Matsunaga A., Kumagai K., Miura S., Nagao T., Hayashi J., et al. Association between fast-migrating low-density lipoprotein subfraction as characterized by capillary isotachophoresis and intima-media thickness of carotid artery. Atherosclerosis 2006, 187:205-212.
85. Shimizu T., Miura S., Tanigawa H., Kuwano T., Zhang B., Uehara Y., Saku K. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler. Thromb. Vasc. Biol. 2014, 34:2246-2253.
86. Zhang B., Miura S., Yanagi D., Noda K., Nishikawa H., Matsunaga A., Shirai K., Iwata A., Yoshinaga K., Adachi H., et al. Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study. Atherosclerosis 2008, 201:353-359.
87. Iwata A., Miura S., Zhang B., Imaizumi S., Uehara Y., Shiomi M., Saku K. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 2011, 218:300-307.
88. Zhang B., Miura S., Fan P., Kumagai K., Takeuchi K., Uehara Y., McMahon M., Rye K.A., Saku K. ApoA-I/phosphatidylcholine discs remodels fast-migrating HDL into slow-migrating HDL as characterized by capillary isotachophoresis. Atherosclerosis 2006, 188:95-101.
89. Zhang B., Bottcher A., Imaizumi S., Noda K., Schmitz G., Saku K. Relation between charge-based apolipoprotein B-containing lipoprotein subfractions and remnant-like particle cholesterol levels. Atherosclerosis 2007, 191:153-161.
90. Zhang B., Matsunaga A., Rainwater D.L., Miura S., Noda K., Nishikawa H., Uehara Y., Shirai K., Ogawa M., Saku K. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study. J. Lipid Res. 2009, 50:1832-1841.
91. Schlenck A., Herbeth B., Siest G., Visvikis S. Characterization and quantification of serum lipoprotein subfractions by capillary isotachophoresis: relationships with lipid, apolipoprotein, and lipoprotein levels. J. Lipid Res. 1999, 40:2125-2133.
92. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26:847-870.
93. Ala-Korpela M., Lankinen N., Salminen A., Suna T., Soininen P., Laatikainen R., Ingman P., Jauhiainen M., Taskinen M.R., Heberger K., et al. The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. Atherosclerosis 2007, 190:352-358.
94. Mallol R., Rodriguez M.A., Heras M., Vinaixa M., Plana N., Masana L., Morris G.A., Correig X. Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy. Anal. Bioanal. Chem. 2012, 402:2407-2415.
95. Rye K.A., Barter P.J. Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochim. Biophys. Acta 2012, 1821:473-480.
96. de la Llera Moya M., McGillicuddy F.C., Hinkle C.C., Byrne M., Joshi M.R., Nguyen V., Tabita-Martinez J., Wolfe M.L., Badellino K., Pruscino L., et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 2012, 222:390-394.
97. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 2012, 60:508-516.
98. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 2010, 21:312-318.
99. Alrasadi K., Awan Z., Alwaili K., Ruel I., Hafiane A., Krimbou L., Genest J. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20mg) versus fenofibrate (200mg) versus extended-release niacin (2g). Am. J. Cardiol. 2008, 102:1341-1347.
100. Yu S., Yarnell J.W., Sweetnam P., Bolton C.H. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 2003, 166:331-338.
101. Kim D.S., Burt A.A., Rosenthal E.A., Ranchalis J.E., Eintracht J.F., Hatsukami T.S., Furlong C.E., Marcovina S., Albers J.J., Jarvik G.P. HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J. Am. Heart Assoc. 2014, 3:e000902.
102. Williams P.T., Feldman D.E. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis 2011, 214:196-202.
103. Williams P.T. Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort. J. Lipid Res. 2012, 53:266-272.
104. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., Bloomfield H.E., Robins S.J. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
105. Ballantyne C.M., Miller M., Niesor E.J., Burgess T., Kallend D., Stein E.A. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am. Heart J. 2012, 163:515-521. (521 e511-513).
106. Swiger K.J., Martin S.S., Blaha M.J., Toth P.P., Nasir K., Michos E.D., Gerstenblith G., Blumenthal R.S., Jones S.R. Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B). J. Am. Heart Assoc. 2014, 3:e000851.
107. Sethi A.A., Sampson M., Warnick R., Muniz N., Vaisman B., Nordestgaard B.G., Tybjaerg-Hansen A., Remaley A.T. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin. Chem. 2010, 56:1128-1137.
108. Guey L.T., Pullinger C.R., Ishida B.Y., O'Connor P.M., Zellner C., Francone O.L., Laramie J.M., Naya-Vigne J.M., Siradze K.A., Deedwania P., et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am. J. Cardiol. 2011, 108:360-366.
109. Superko H.R., Pendyala L., Williams P.T., Momary K.M., King S.B., Garrett B.C. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J. Clin. Lipidol. 2012, 6:496-523.
110. Chantepie S., Bochem A.E., Chapman M.J., Hovingh G.K., Kontush A. High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity. PLoS ONE 2012, 7:e49336.
111. Ibanez B., Giannarelli C., Cimmino G., Santos-Gallego C.G., Alique M., Pinero A., Vilahur G., Fuster V., Badimon L., Badimon J.J. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 2012, 220:72-77.
112. Serfaty-Lacrosniere C., Civeira F., Lanzberg A., Isaia P., Berg J., Janus E.D., Smith M.P., Pritchard P.H., Frohlich J., Lees R.S., et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994, 107:85-98.
113. Dobiasova M., Frohlich J. Measurement of fractional esterification rate of cholesterol in plasma depleted of apoprotein B containing lipoprotein: methods and normal values. Physiol. Res. 1996, 45:65-73.
114. Frohlich J., Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin. Chem. 2003, 49:1873-1880.
115. Dobiasova M., Adler L., Ohta T., Frohlich J. Effect of labeling of plasma lipoproteins with [(3)H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma. J. Lipid Res. 2000, 41:1356-1357.
116. Hafiane A., Bielicki J.K., Johansson J.O., Genest J. Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. Biochim. Biophys. Acta 2014, 1842:1498-1512.
117. Albers J.J., Chen C.H., Adolphson J.L. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J. Lipid Res. 1981, 22:1206-1213.
118. Dullaart R.P., Tietge U.J., Kwakernaak A.J., Dikkeschei B.D., Perton F., Tio R.A. Alterations in plasma lecithin:cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: implications for cardiac outcome. Atherosclerosis 2014, 234:185-192.
119. Vaisman B.L., Remaley A.T. Measurement of lecithin-cholesterol acyltransferase activity with the use of a peptide-proteoliposome substrate. Methods Mol. Biol. 2013, 1027:343-352.
120. Calabresi L., Gomaraschi M., Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1724-1731.
121. Calabresi L., Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovasc. Med. 2010, 20:50-53.
122. Kunnen S., Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?. J. Lipid Res. 2012, 53:1783-1799.
123. Oldoni F., Sinke R.J., Kuivenhoven J.A. Mendelian disorders of high-density lipoprotein metabolism. Circ. Res. 2014, 114:124-142.
124. Rader D.J., Alexander E.T., Weibel G.L., Billheimer J., Rothblat G.H. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 2009, 50:S189-194. (Suppl.).
125. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., Seilhamer J.J., Vaughan A.M., Oram J.F. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 1999, 104:R25-31.
126. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., French B.C., Phillips J.A., Mucksavage M.L., Wilensky R.L., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364:127-135.
127. Yamamoto S., Yancey P.G., Ikizler T.A., Jerome W.G., Kaseda R., Cox B., Bian A., Shintani A., Fogo A.B., Linton M.F., et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J. Am. Coll. Cardiol. 2012, 60:2372-2379.
128. Doonan R.J., Hafiane A., Lai C., Veinot J.P., Genest J., Daskalopoulou S.S. Cholesterol efflux capacity, carotid atherosclerosis, and cerebrovascular symptomatology. Arterioscler. Thromb. Vasc. Biol. 2014, 34:921-926.
129. Hafiane A., Jabor B., Ruel I., Ling J., Genest J. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am. J. Cardiol. 2014, 113:249-255.
130. Low H., Hoang A., Sviridov D. Cholesterol efflux assay. J. Vis. Exp. 2012, e3810.
131. Rothblat G.H., de la Llera-Moya M., Favari E., Yancey P.G., Kellner-Weibel G. Cellular cholesterol flux studies: methodological considerations. Atherosclerosis 2002, 163:1-8.
132. Li X.M., Tang W.H., Mosior M.K., Huang Y., Wu Y., Matter W., Gao V., Schmitt D., Didonato J.A., Fisher E.A., et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1696-1705.
133. Eckardstein A. Tachometer for reverse cholesterol transport?. J. Am. Heart Assoc. 2012, 1:e003723.
134. Hoang A., Drew B.G., Low H., Remaley A.T., Nestel P., Kingwell B.A., Sviridov D. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur. Heart J. 2012, 33:657-665.
135. Barrans A., Collet X., Barbaras R., Jaspard B., Manent J., Vieu C., Chap H., Perret B. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J. Biol. Chem. 1994, 269:11572-11577.
136. Denis M., Haidar B., Marcil M., Bouvier M., Krimbou L., Genest J. Characterization of oligomeric human ATP binding cassette transporter A1. Potential implications for determining the structure of nascent high density lipoprotein particles. J. Biol. Chem. 2004, 279:41529-41536.
137. Sankaranarayanan S., Kellner-Weibel G., de la Llera-Moya M., Phillips M.C., Asztalos B.F., Bittman R., Rothblat G.H. A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J. Lipid Res. 2011, 52:2332-2340.
138. Solanko L.M., Honigmann A., Midtiby H.S., Lund F.W., Brewer J.R., Dekaris V., Bittman R., Eggeling C., Wustner D. Membrane orientation and lateral diffusion of BODIPY-cholesterol as a function of probe structure. Biophys. J. 2013, 105:2082-2092.
139. Omura R., Nagao K., Kobayashi N., Ueda K., Saito H. Direct detection of ABCA1-dependent HDL formation based on lipidation-induced hydrophobicity change in apoA-I. J. Lipid Res. 2014, 55:2423-2431.
140. Niedziela-Majka A., Lad L., Chisholm J.W., Lagpacan L., Schwartz K., Hung M., Jin D., Fung W., Brendza K.M., Liu X., et al. Lipid-sensing high-throughput ApoA-I assays. J. Biomol. Screen. 2012, 17:1050-1061.
141. Cavigiolio G., Geier E.G., Shao B., Heinecke J.W., Oda M.N. Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J. Biol. Chem. 2010, 285:18847-18857.
142. Borja M.S., Zhao L., Hammerson B., Tang C., Yang R., Carson N., Fernando G., Liu X., Budamagunta M.S., Genest J., et al. HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS ONE 2013, 8:e71541.
143. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., Byun J., Vuletic S., Kassim S., Singh P., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117:746-756.
144. Navab M., Hama S.Y., Anantharamaiah G.M., Hassan K., Hough G.P., Watson A.D., Reddy S.T., Sevanian A., Fonarow G.C., Fogelman A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 2000, 41:1495-1508.
145. Ansell B.J., Navab M., Hama S., Kamranpour N., Fonarow G., Hough G., Rahmani S., Mottahedeh R., Dave R., Reddy S.T., et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751-2756.
146. Breton C.V., Yin F., Wang X., Avol E., Gilliland F.D., Araujo J.A. HDL anti-oxidant function associates with LDL level in young adults. Atherosclerosis 2014, 232:165-170.
147. White C.R., Smythies L.E., Crossman D.K., Palgunachari M.N., Anantharamaiah G.M., Datta G. Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2631-2639.
148. Navab M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 2011, 8:222-232.
149. Suzuki M., Pritchard D.K., Becker L., Hoofnagle A.N., Tanimura N., Bammler T.K., Beyer R.P., Bumgarner R., Vaisar T., de Beer M.C., et al. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 2010, 122:1919-1927.
150. Schindhelm R.K., van der Zwan L.P., Teerlink T., Scheffer P.G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?. Clin. Chem. 2009, 55:1462-1470.
151. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 2001, 42:1308-1317.
152. Kelesidis T., Currier J.S., Huynh D., Meriwether D., Charles-Schoeman C., Reddy S.T., Fogelman A.M., Navab M., Yang O.O. A biochemical fluorometric method for assessing the oxidative properties of HDL. J. Lipid Res. 2011, 52:2341-2351.
153. Watson C.E., Weissbach N., Kjems L., Ayalasomayajula S., Zhang Y., Chang I., Navab M., Hama S., Hough G., Reddy S.T., et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 2011, 52:361-373.
154. Kelesidis T., Reddy S.T., Huynh D., Meriwether D., Fogelman A.M., Navab M., Yang O.O. Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis. 2012, 11:87.
155. Browne R.W., Koury S.T., Marion S., Wilding G., Muti P., Trevisan M. Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin. Chem. 2007, 53:310-317.
156. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
157. Yin F., Lawal A., Ricks J., Fox J.R., Larson T., Navab M., Fogelman A.M., Rosenfeld M.E., Araujo J.A. Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1153-1161.
158. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., Chroni A., Yonekawa K., Stein S., Schaefer N., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 2011, 121:2693-2708.
159. Gugliucci A., Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta 2015, 439:5-13.
160. Razavi A.E., Ani M., Pourfarzam M., Naderi G.A. Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity. J. Res. Med. Sci. 2012, 17:1020-1026.
161. Soran H., Younis N.N., Charlton-Menys V., Durrington P. Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol. 2009, 20:265-274.
162. Shao B., Tang C., Sinha A., Mayer P.S., Davenport G.D., Brot N., Oda M.N., Zhao X.Q., Heinecke J.W. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ. Res. 2014, 114:1733-1742.
163. McMillen T.S., Heinecke J.W., LeBoeuf R.C. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 2005, 111:2798-2804.
164. Charles-Schoeman C., Lee Y.Y., Grijalva V., Amjadi S., FitzGerald J., Ranganath V.K., Taylor M., McMahon M., Paulus H.E., Reddy S.T. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2012, 71:1157-1162.
165. Shao B., Pennathur S., Heinecke J.W. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J. Biol. Chem. 2012, 287:6375-6386.
166. Gomaraschi M., Ossoli A., Pozzi S., Nilsson P., Cefalu A.B., Averna M., Kuivenhoven J.A., Hovingh G.K., Veglia F., Franceschini G., et al. eNOS activation by HDL is impaired in genetic CETP deficiency. PLoS ONE 2014, 9:e95925.
167. Muller U., Matsuo Y., Lauber M., Walther C., Oberbach A., Schuler G., Adams V. Correlation between endothelial function measured by finger plethysmography in children and HDL-mediated eNOS activation - a preliminary study. Metabolism 2013, 62:634-637.
168. Morawietz H., Goettsch W., Brux M., Reimann M., Bornstein S.R., Julius U., Ziemssen T. Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. Atheroscler. Suppl. 2013, 14:107-113.
169. Bruyndonckx L., Radtke T., Eser P., Vrints C.J., Ramet J., Wilhelm M., Conraads V.M. Methodological considerations and practical recommendations for the application of peripheral arterial tonometry in children and adolescents. Int. J. Cardiol. 2013, 168:3183-3190.
170. Kastelein J.J., Duivenvoorden R., Deanfield J., de Groot E., Jukema J.W., Kaski J.C., Munzel T., Taddei S., Lehnert V., Burgess T., et al. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr. Med. Res. Opin. 2011, 27:141-150.
171. Luscher T.F., Taddei S., Kaski J.C., Jukema J.W., Kallend D., Munzel T., Kastelein J.J., Deanfield J.E. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur. Heart J. 2012, 33:857-865.
172. Adams V., Besler C., Fischer T., Riwanto M., Noack F., Hollriegel R., Oberbach A., Jehmlich N., Volker U., Winzer E.B., et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ. Res. 2013, 113:1345-1355.
173. Riwanto M., Rohrer L., Roschitzki B., Besler C., Mocharla P., Mueller M., Perisa D., Heinrich K., Altwegg L., von Eckardstein A., et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013, 127:891-904.
174. Brouchet L., Krust A., Dupont S., Chambon P., Bayard F., Arnal J.F. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 2001, 103:423-428.
175. Lindner V., Fingerle J., Reidy M.A. Mouse model of arterial injury. Circ. Res. 1993, 73:792-796.
176. Shah A.S., Tan L., Long J.L., Davidson W.S. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 2013, 54:2575-2585.
177. Davidson W.S., Silva R.A., Chantepie S., Lagor W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 2009, 29:870-876.
178. Heinecke J.W. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J. Lipid Res. 2009, 50:S167-171. (Suppl.).
179. Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr. Vasc. Pharmacol. 2012, 10:410-421.
180. Vaisar T., Mayer P., Nilsson E., Zhao X.Q., Knopp R., Prazen B.J. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin. Chim. Acta 2010, 411:972-979.
181. Shevchenko A., Tomas H., Havlis J., Olsen J.V., Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat. Protoc. 2006, 1:2856-2860.
182. Gordon S.M., Deng J., Lu L.J., Davidson W.S. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 2010, 9:5239-5249.
183. Holzer M., Wolf P., Curcic S., Birner-Gruenberger R., Weger W., Inzinger M., El-Gamal D., Wadsack C., Heinemann A., Marsche G. Psoriasis alters HDL composition and cholesterol efflux capacity. J. Lipid Res. 2012, 53:1618-1624.
184. Burillo E., Vazquez J., Jorge I. Quantitative proteomics analysis of high-density lipoproteins by stable 18O-isotope labeling. Methods Mol. Biol. 2013, 1000:139-156.
185. Yetukuri L., Soderlund S., Koivuniemi A., Seppanen-Laakso T., Niemela P.S., Hyvonen M., Taskinen M.R., Vattulainen I., Jauhiainen M., Oresic M. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J. Lipid Res. 2010, 51:2341-2351.
186. Pluskal T., Castillo S., Villar-Briones A., Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinf. 2010, 11:395.
187. Koy C., Mikkat S., Raptakis E., Sutton C., Resch M., Tanaka K., Glocker M.O. Matrix-assisted laser desorption/ionization- quadrupole ion trap-time of flight mass spectrometry sequencing resolves structures of unidentified peptides obtained by in-gel tryptic digestion of haptoglobin derivatives from human plasma proteomes. Proteomics 2003, 3:851-858.
188. Simons B., Kauhanen D., Sylvänne T., Tarasov K., Duchoslav E., Ekroos K. Shotgun lipidomics by sequential precursor ion fragmentation on a hybrid quadrupole time-of-flight mass spectrometer. Metabolites 2012, 2:195-213.
189. Li L., Han J., Wang Z., Liu J., Wei J., Xiong S., Zhao Z. Mass spectrometry methodology in lipid analysis. Int. J. Mol. Sci. 2014, 15:10492-10507.
190. Han X., Gross R.W. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res. 2003, 44:1071-1079.
191. Blanksby S.J., Mitchell T.W. Advances in mass spectrometry for lipidomics. Annu Rev Anal Chem (Palo Alto, Calif) 2010, 3:433-465.
192. Scherer M., Bottcher A., Liebisch G. Lipid profiling of lipoproteins by electrospray ionization tandem mass spectrometry. Biochim. Biophys. Acta 2011, 1811:918-924.
193. Retra K., Bleijerveld O.B., van Gestel R.A., Tielens A.G., van Hellemond J.J., Brouwers J.F. A simple and universal method for the separation and identification of phospholipid molecular species. Rapid Commun. Mass Spectrom. 2008, 22:1853-1862.
194. Isaac G. Electrospray ionization tandem mass spectrometry (ESI-MS/MS)-based shotgun lipidomics. Methods Mol. Biol. 2011, 708:259-275.
195. Weir J.M., Wong G., Barlow C.K., Greeve M.A., Kowalczyk A., Almasy L., Comuzzie A.G., Mahaney M.C., Jowett J.B., Shaw J., et al. Plasma lipid profiling in a large population-based cohort. J. Lipid Res. 2013, 54:2898-2908.
196. Stubiger G., Aldover-Macasaet E., Bicker W., Sobal G., Willfort-Ehringer A., Pock K., Bochkov V., Widhalm K., Belgacem O. Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS. Atherosclerosis 2012, 224:177-186.
197. Lackner K.J., Schmitz G. beta-VLDL of patients with type III hyperlipoproteinemia interferes with homogeneous determination of HDL-cholesterol based on polyethylene glycol-modified enzymes. Clin. Chem. 1998, 44:2546-2548.
198. Degorce F., Card A., Soh S., Trinquet E., Knapik G.P., Xie B. HTRF: a technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr. Chem. Genomics 2009, 3:22-32.
199. Jia Y., Quinn C.M., Gagnon A.I., Talanian R. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal. Biochem. 2006, 356:273-281.
200. Fournier M.L., Gilmore J.M., Martin-Brown S.A., Washburn M.P. Multidimensional separations-based shotgun proteomics. Chem. Rev. 2007, 107:3654-3686.
201. Lee C.Y., Lesimple A., Larsen A., Mamer O., Genest J. ESI-MS quantitation of increased sphingomyelin in Niemann-Pick disease type B HDL. J. Lipid Res. 2005, 46:1213-1228.
202. Yamaguchi Y., Kunitomo M., Haginaka J. Assay methods of modified lipoproteins in plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2002, 781:313-330.